When it comes to weight loss, many of us are looking for something simple, effective, and—most importantly—doable. That’s ...

Novo Nordisk secured U.S. regulatory approval for its weight-loss pill, giving the Danish drugmaker a shot at reclaiming ...

Highly anticipated Phase 2 data for Amgen’s obesity drug show that on average, participants lost about 20% of their weight after one year of treatment, results that put the experimental medicine in ...

In a head-to-head tussle between two obesity drugs, tirzepatide came out on top of semaglutide for weight loss, according to top-line results from the SURMOUNT-5 trial released by Eli Lilly on ...

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a late-stage trial, outperforming its blockbuster drug Zepbound and reinforcing ...